

1 **High-sensitivity cardiac troponin I and risk of dementia: 25-year longitudinal study in**  
2 **the Whitehall II cohort**

3  
4 Yuntao Chen<sup>ab</sup>, Martin Shipley<sup>a</sup>, Atul Anand<sup>c</sup>, Dorien M Kimenai<sup>c</sup>, Klaus P Ebmeier<sup>d</sup>,  
5 Severine Sabia<sup>ae</sup>, Archana Singh-Manoux<sup>e</sup>, John Deanfield<sup>f</sup>, Mika Kivimaki<sup>a</sup>, Gill  
6 Livingston<sup>a</sup>, Nicholas L Mills<sup>cg</sup>, Eric J Brunner<sup>b</sup>

7  
8 a Division of Psychiatry, University College London, London, UK

9 b Department of Epidemiology and Public Health, University College London, London, UK

10 c British Heart Foundation Centre for Cardiovascular Science, University of Edinburgh,  
11 Edinburgh, UK

12 d Department of Psychiatry and Wellcome Centre for integrative Neuroimaging, University  
13 of Oxford, Oxford, UK

14 e Inserm U1153, Epidemiology of Ageing and Neurodegenerative diseases, Universite de  
15 Paris, Paris, France

16 f Institute of Cardiovascular Science, University College London, London, UK

17 g Usher Institute, University of Edinburgh, Edinburgh, UK

18

19 Correspondence to:

20 Yuntao Chen

21 Division of Psychiatry, University College London, London, UK

22 Maple House, 149 Tottenham Court Road, London, W1T 7NF

23 Email address: [yuntao.chen@ucl.ac.uk](mailto:yuntao.chen@ucl.ac.uk)

24

25 **Abstract**

26

27 **Objective** We hypothesise that subclinical myocardial injury during midlife, indexed by  
28 increases in cardiac troponin I, is associated with accelerated cognitive decline, smaller  
29 structural brain volume, and higher risk of dementia.

30

31 **Design** Longitudinal cohort study

32

33 **Setting** Civil service departments in London (Whitehall II study)

34

35 **Participants** 5985 participants aged 45-69 had cardiac troponin I measured by high-  
36 sensitivity assay at baseline (1997-99) for prospective cohort analyses. A nested case-control  
37 sample of 3475 participants (695 dementia cases and 2780 matched controls) was used for  
38 backward cardiac troponin I trajectory analysis. 641 participants provided magnetic  
39 resonance imaging (MRI) scans for brain volume analysis.

40

41 **Main outcome measures** Incident dementia cases were ascertained from national hospital  
42 episode statistics, mental health and mortality registers until 2023. Cognitive testing was  
43 performed at six waves over 25 years (1997-99, 2002-04, 2007-09, 2012-13, 2015-16, 2019-  
44 22). Brain volume metrics were derived from structural MRI scans (2012-16).

45

46 **Results** For prospective cohort analyses, 606 (10.1%) incident cases of dementia were  
47 recorded over a median follow-up of 24.8 years. Doubling of cardiac troponin was associated  
48 with 11% higher risk of dementia (HR=1.11, 95% CI: 1.04 to 1.19). Participants with  
49 increased cardiac troponin at baseline had a faster decline of cognitive function with age.  
50 Compared to participants with concentrations below the limit of quantitation (<2.5 ng/L),  
51 those in the upper third (>5.2 ng/L) had similar global cognitive z score at age 60, but had  
52 0.10 (95% CI: 0.02 to 0.18) standard deviations lower score at age 80, and 0.19 (0.03 to 0.35)  
53 standard deviations lower score at age 90. Participants with dementia had increased cardiac  
54 troponin concentrations compared with those without dementia between 7 and 25 years  
55 before diagnosis. Compared to those with low cardiac troponin level (<2.5 ng/L at baseline)  
56 those with concentrations >5.2 ng/L had lower grey matter volume and higher hippocampal  
57 atrophy 15 years later, equivalent to ageing effects of 2.7 and 3 years, respectively.

58

59 **Conclusions** Subclinical myocardial injury at midlife was associated with higher dementia  
60 risk in later life.

61

62 **What is already known on this topic**

63 A systematic review of observational studies suggests higher cardiac troponin concentrations  
64 are associated with poorer cognitive function and increased dementia risk. Formal meta-  
65 analysis was not performed due to the small number of available studies.

66

67 Existing studies assessed cardiac troponin once and had relatively short follow-up time.  
68 Evidence is lacking on the time course of cardiac troponin level before diagnosis in dementia  
69 cases compared with controls.

70

71

72 **What this study adds**

73 People with increased cardiac troponin I concentrations in mid-life had faster cognitive  
74 decline and were more likely to develop dementia over 25 years of follow-up. Backward  
75 trajectory analysis using three measurements using a high-sensitivity assay showed that  
76 people with dementia had higher cardiac troponin levels as early as 25 years before dementia  
77 diagnosis compared with those without dementia. People in the magnetic resonance imaging  
78 subcohort with higher cardiac troponin I concentrations at baseline had lower grey matter  
79 volume and hippocampal atrophy 15 years later.

80

81 Subclinical myocardial injury in midlife, by indicating long-term risk of dementia, is unlikely  
82 to be due to preclinical changes before dementia onset and may lie on the causal pathway to  
83 dementia.

84

85

## 86 **Introduction**

87 Emerging evidence suggests an intertwined relation between the health of heart and brain.<sup>1-3</sup>  
88 The 2024 Lancet Commission on dementia suggests 17% of dementia cases can be prevented  
89 or delayed by modifying cardiovascular risk factors including high cholesterol, physical  
90 inactivity, diabetes, hypertension, obesity, smoking and excessive alcohol consumption.<sup>4</sup>  
91 People with poor cardiovascular health, even in the absence of clinical coronary heart disease,  
92 have increased risk of dementia.<sup>5,6</sup>

93  
94 Cardiac troponin is a commonly-used cardiac biomarker and its utility has been extended  
95 with introduction of high-sensitivity assays.<sup>7-9</sup> Modest elevation in cardiac troponin in  
96 apparently healthy populations is linked with increased risk of dementia, although existing  
97 studies have only assessed cardiac troponin once and had relatively short follow-ups.<sup>10-12</sup>  
98 Consequently, it is unknown how long before dementia diagnosis cardiac troponin levels  
99 become increased among cases relative to controls. Further, few studies have prospectively  
100 examined whether cardiac troponin in midlife is a marker of potential preclinical changes in  
101 dementia-related measures such as cognition and brain volume. Consistent results from these  
102 different lines of research would strengthen the evidence on the role of subclinical  
103 myocardial injury in the aetiology of dementia.

104  
105 This study uses longitudinal data from the Whitehall II cohort study spanning 25 years and  
106 three measurements of cardiac troponin I based on a high-sensitivity assay. We examined 1)  
107 the long-term association of cardiac troponin I at study baseline with cognitive trajectory and  
108 incident dementia in prospective analyses; 2) how long before diagnosis of dementia the  
109 cardiac troponin I level has been elevated by modelling the backward trajectory of cardiac  
110 troponin I; and 3) the association of cardiac troponin I with brain volume measures assessed  
111 15 years later in a substudy of structural magnetic resonance imaging.

112

## 113 **Methods**

### 114 **Study population**

115 The Whitehall II study is an ongoing longitudinal study of 10 308 people recruited from the  
116 British Civil Service in 1985-88. Participants had clinical examinations of behavioural and  
117 biomedical factors in 8 waves (1985-88, 1991-94, 1997-99, 2002-04, 2007-09, 2012-13,

118 2015-16, 2019-22). Written informed consent from participants was renewed at each contact.  
119 The baseline for this study is 1997-99 when cardiac troponin was first measured. We  
120 included 6 waves of clinical examination until 2022. Disease and death data up to March  
121 2023 were obtained through linkage to electronic health records of the UK National Health  
122 Service.

123

## 124 **Measures**

### 125 **High-sensitivity cardiac troponin I**

126 Cardiac troponin I was measured using stored blood samples at three waves (1997-99, 2007-  
127 09, 2012-13).<sup>9,13</sup> Blood samples for each wave were handled according to a standardised  
128 protocol. Fasting venous blood samples were collected, centrifuged, and serum was stored in  
129 aliquots at -80 °C until batch analysis was performed. Cardiac troponin I concentrations were  
130 measured using the Siemens Atellica Immunoassay High Sensitivity Troponin I assay  
131 (Siemens Healthineers, Erlangen, Germany). This assay has a limit of blank of 0.5 ng/L, limit  
132 of detection of 1.6 ng/L, and a limit of quantitation of 2.5 ng/L. In the analyses, we assigned  
133 0.5 ng/L to those with cardiac troponin concentration below the limit of blank. The sex-  
134 specific 99<sup>th</sup> centile upper reference limits in the general population used for clinical referral  
135 are 34 ng/L and 53 ng/L in females and males, respectively.

136

### 137 **Cognitive function**

138 The cognitive test battery was introduced to the Whitehall II clinic in 1997-99 and repeated at  
139 all subsequent clinical assessments. We included all six waves of cognition data between  
140 1997 (aged 45-69 years) and 2022 (aged 68-92 years). The tests have good test-retest  
141 reliability (range 0.6-0.9), assessed in 556 participants and retested within three months in  
142 1997-99. Three cognitive domains (memory, executive function, and fluency) were assessed.  
143 Memory was assessed using a 20-word free recall test. Executive function was assessed with  
144 the Alice Heim 4-I test. Fluency was assessed using measures of phonemic and semantic  
145 fluency. Participant were asked to recall in writing as many words beginning with “s”  
146 (phonemic fluency) and as many animal names (semantic fluency) as they could. One minute  
147 was allowed for each test.

148

149 Based on three cognitive domains, we created a global cognitive score incorporating all tests  
150 described above by firstly using the distribution of the first wave of cognitive data (1997-99)  
151 to standardise the raw scores for each domain to z scores. We summed these z scores and

152 restandardised them to yield the global score, an approach that minimises measurement error  
153 inherent individual tests.<sup>14</sup>

154

## 155 **Dementia**

156 We used three registers (the national hospital episode statistics (HES) database, the Mental  
157 Health Service Data Set, and the mortality register) to ascertain dementia using ICD-10 codes  
158 F00-F03, F05.1, G30, and G31. Record linkage was available up to 1 March 2023. Date of  
159 dementia was set as the earliest record of a diagnostic code for dementia in any of the three  
160 ascertainment databases. As our outcome was incident dementia, participants with dementia  
161 at baseline were excluded.

162

## 163 **Brain volume**

164 771 participants, randomly selected from Whitehall II phase 11 (2012-13), received  
165 multimodal brain magnetic resonance imaging (MRI) scans at the Oxford Centre for  
166 Functional MRI of the Brain, as part of the Whitehall II imaging substudy.<sup>15</sup> Due to a scanner  
167 upgrade, two MRI scanners were used: a 3T Siemens Magnetom Verio scanner (Erlangen,  
168 Germany) with a 32-channel head coil (April 2012 to December 2014) and a 3T Siemens  
169 Prisma Scanner (Erlangen, Germany) with a 64-channel head-neck coil in the same centre  
170 (July 2015 to December 2016). The scan parameters were identical or closely matched  
171 between scanners. Analyses were adjusted for scanner type. Brain tissues were segmented  
172 using an automated segmentation tool, which extracts measures of total grey matter, white  
173 matter, and cerebrospinal fluid.<sup>15</sup> Intracranial volume was calculated as the sum of total grey  
174 matter, white matter, and cerebrospinal fluid. All volumes were normalised by converting  
175 them to percentages of the intracranial volume. Burden of white matter hyperintensities was  
176 estimated using the Fazekas visual rating scale.<sup>16</sup> A score (range 0-3) was assigned for deep  
177 white matter and periventricular areas based on the size, location, and confluence of lesions.  
178 We used the sum of the two scores to estimate the total burden of white matter intensities.  
179 Hippocampal atrophy was estimated using the Scheltens score assessed by three clinicians  
180 independently.<sup>17</sup>

181

## 182 **Clinical characteristics**

183 We included sociodemographic, health behaviours, and health status at baseline (1997-99) as  
184 covariates: age, sex, education (less than secondary school, secondary school, university),  
185 occupational position based on British Civil Service employment grade (administrative

186 grades, professional or executive grades, clerical or support grades), birth cohort defined  
187 based on sociohistorical events<sup>18</sup> (Depression-era cohort born 1930-38, World War 2 cohort  
188 born 1939-45, Post-war cohort born 1946-52); smoking status (never, former, current),  
189 alcohol consumption (non-drinker, moderate consumption: 1-14 units/week in women or 1-  
190 21 units/week in men, heavy consumption: >14 units/week in women or >21 units/week in  
191 men), physical activity (hours of moderate or vigorous exercise/week, categorised as low <1  
192 hour, moderate 1-2.4 hour, high  $\geq 2.5$  hour); body mass index (BMI, kg/m<sup>2</sup>), systolic blood  
193 pressure (SBP, mmHg), diastolic blood pressure (DBP, mmHg), fast glucose (mmol/l), total  
194 cholesterol (mmol/L), diabetes (doctor-diagnosed diabetes or use of diabetes medication).  
195 Cardiovascular disease was identified via linkage to national hospital episode statistics (HES)  
196 data, recording any diagnosis of coronary heart disease (ICD-9 codes 410-414 and 429; ICD-  
197 10 codes I20-I25) or stroke (ICD-10 codes I60-I64 and G45).

198

### 199 **Statistical analysis**

200 *Association between cardiac troponin I at baseline and incidence of dementia.*

201 We included all participants free of dementia or cardiovascular disease, who had data on  
202 cardiac troponin I at baseline (1997-99). These participants were followed-up to date of  
203 record of dementia, death, or 1 March 2023, whichever came first. Cox proportional hazard  
204 models were used to examine the association between cardiac troponin I and dementia  
205 incidence. We modelled cardiac troponin I both continuously and categorically. For the  
206 continuous analysis, we used log<sub>2</sub> transformation as the cardiac troponin levels were right-  
207 skewed. For the categorical analysis, we used the following categories: <2.5 ng/L (below the  
208 limit of quantitation threshold, reference group), 2.5-3.4 ng/L, 3.5-5.2 ng/L, >5.2 ng/L. The  
209 latter three groups were cut based on tertiles of troponin measurements above the limit of  
210 quantitation threshold. We also modelled cardiac troponin I using natural cubic spline  
211 function to visualise possible non-linear association with dementia incidence. In the above  
212 analyses, we used age as time scale and adjusted for sex, ethnicity, education level,  
213 occupational position, alcohol consumption, smoking status, physical activity, BMI, SBP,  
214 DBP, glucose, and total cholesterol at baseline.

215

216 *Association between cardiac troponin I at baseline and cognitive trajectory.*

217 We included all participants that were free of dementia and cardiovascular disease at baseline,  
218 had data on cardiac troponin I at baseline, and had at least one measurement of cognitive  
219 function among 6 repeated measurements between 1997 and 2022. Mixed models with age as

220 the time scale were used to examine whether cardiac troponin I at baseline was associated  
221 with cognitive trajectories. The model included sex, ethnicity, education level, occupational  
222 position, birth cohort, cardiac troponin I ( $\log_2$  transformed), age, age<sup>2</sup>, and interactions of all  
223 the covariates with age and age<sup>2</sup>. A likelihood ratio test was conducted for the interaction of  
224 cardiac troponin I with age and age<sup>2</sup> to examine whether the cognitive trajectory differed in  
225 different cardiac troponin I levels at baseline. We replicated the analysis using categorised  
226 cardiac troponin I in 4 groups as above to relax the linear assumption and to visualise and  
227 present the results. We plotted the cognitive trajectory by different baseline cardiac troponin  
228 level, and statistically compared cognitive scores for different troponin I groups at age 60, 70,  
229 80, and 90. We repeated the analysis by further accounting for alcohol consumption, smoking  
230 status, physical activity, BMI, SBP, DBP, glucose, and total cholesterol.

231

232 *Backward trajectory of cardiac troponin I before dementia.*

233 We included all participants who were free of dementia and cardiovascular disease at  
234 baseline and had at least one cardiac troponin measurement before end of follow-up. We used  
235 a nested case-control design to compare the trajectory of cardiac troponin I in those who  
236 developed dementia and those did not. Each dementia case was matched to 4 controls at the  
237 diagnostic date. We used random sampling with replacement (i.e., same control is possible to  
238 be matched with different cases). The eligibility of the control sample is: 1) free of dementia  
239 at the diagnostic date; 3) of similar sex and age ( $\pm 3$  years); 4) of same education level. In the  
240 sensitivity analysis, we further matched with same cardiovascular disease to see whether the  
241 effect was attenuated.

242

243 We used retrospective time since the matching date as the time scale. Time 0 was date of  
244 dementia diagnosis for each quintet (1 case and 4 matched controls). A latent process mixed  
245 model<sup>19</sup> was used to model the trajectory of cardiac troponin I ( $\log_2$  transformed). The model  
246 included time, time<sup>2</sup>, index age (age at time 0), sex, education level, case indicator (coded as  
247 1 for cases and 0 for controls), and interactions of all the covariates (index age, sex, education  
248 level, and case indicator) with time and time<sup>2</sup>. Wald test was used for the interaction of case  
249 indicator with time and time<sup>2</sup> to examine whether the trajectory of cardiac troponin I differed  
250 between cases and controls. We also used the Wald tests to compare the differences of  
251 predicted mean cardiac troponin I levels between cases and controls at different time points  
252 before dementia diagnosis.

253



254 *Association between cardiac troponin I at baseline and brain volume.*

255 We included participants that were free of dementia and cardiovascular disease, did not have  
256 missing data for cardiac troponin I at phase 5 (1997-99), and had MRI scans between 2012-  
257 16. Linear regression models were used to examine the association between cardiac troponin  
258 I at baseline and whole brain volume (sum of grey and white matter), grey matter volume,  
259 and white matter volume. Poisson regression models were used to examine the association of  
260 baseline cardiac troponin I with white matter hyperintensity burden and hippocampal atrophy.  
261 We modelled cardiac troponin I both continuously and categorically aforementioned. The  
262 models were all adjusted for age at MRI assessment, sex, education, occupational position,  
263 smoking status, and alcohol consumption.

264

265 We used simple imputation for the covariates with missing values. All analyses were  
266 performed using R statistical software, version 4.4.1.

267

## 268 **Patient and public involvement**

269 Participants of the Whitehall II study were not involved in setting the research question or the  
270 outcome measures, nor in developing plans for recruitment, design, or implementation of the  
271 study. No participants were asked for advice on interpretation or writing up of results.  
272 However, all results are disseminated to study participants via newsletters and our website,  
273 which has a participant portal (<https://www.ucl.ac.uk/psychiatry/research/mental-health-older-people/whitehall-ii/participants-area>).  
274

275

## 276 **Results**

277 7299 participants had at least one measure of cardiac troponin I. They did not have dementia  
278 at baseline. After excluding participants with cardiovascular disease (n=62) at baseline, 7237  
279 participants were included. Among these participants, 5985 had cardiac troponin at baseline.  
280 606 (10.1%) cases of dementia were recorded over a median follow-up time of 24.8  
281 (interquartile range 23.3-25.1) years. Baseline characteristics, as well as by cardiac troponin I  
282 levels and dementia status at follow-up, are presented in Table 1. Participants with higher  
283 cardiac troponin I were older, more likely to be men and from higher educational and  
284 occupational group. They had higher BMI, SBP, DBP, and glucose level. Compared with  
285 those who were dementia free at the end of follow-up, people with incident dementia were

286 older, more likely to be women, and from lower education and occupational group. They had  
287 higher BMI, glucose, SBP and total cholesterol level.

288

### 289 **Association between cardiac troponin I at baseline and incidence of dementia**

290 5985 participants free of diagnosed cardiovascular disease and dementia at baseline (age  
291 range 45-69) were included in the analyses. Every doubling of cardiac troponin I was  
292 associated with 11% higher risk of dementia (HR=1.11, 95% CI: 1.04 to 1.19). The  
293 association did not differ between age group ( $\leq 60$  vs  $>60$  years) ( $P_{\text{interaction}}=0.76$ ) or sex  
294 ( $P_{\text{interaction}}=0.32$ ). Compared with those with cardiac troponin I below quantification limit  
295 ( $<2.5$  ng/L), participants with cardiac troponin I  $>5.2$  ng/L had 43% higher risk of dementia  
296 (HR=1.43, 95% CI: 1.13 to 1.80) (Table 2). We also plotted the association between cardiac  
297 troponin I and dementia incidence using natural cubic splines (Figure S1). The result was  
298 consistent with analysis with categorised cardiac troponin I group and showed continuously  
299 increased risk of dementia as cardiac troponin I increases. The increase in dementia risk  
300 tended to be smaller as troponin I level increased, however this was not a statistically  
301 significant effect ( $P$  for non-linearity=0.22).

302

### 303 **Association between cardiac troponin I at baseline and cognitive trajectory**

304 5895 participants free of diagnosed cardiovascular disease and dementia at baseline with one  
305 or more measurements of cognitive data were included in the analyses (90 participants  
306 without any cognitive data were excluded). Of them, 2508 (42.5%) had cognitive data at all  
307 six waves, 1102 (18.7%) at five waves, 652 (11.1%) at four waves, 555 (9.4%) at three waves,  
308 500 (8.5%) at two waves, and 578 (9.8%) at only one wave. Cognitive trajectory differed by  
309 cardiac troponin I after adjusting for sex, ethnicity, education level, occupational position,  
310 birth cohort (continuous values:  $P_{\text{interaction}}=0.07$ ; grouped values: interaction  $P=0.0012$ ).  
311 Participants with higher cardiac troponin I at baseline had a faster decline of cognitive  
312 function with age (Figure 1). Compared with participants with cardiac troponin I  $<2.5$  ng/L,  
313 those with cardiac troponin I  $>5.2$  ng/L had similar global cognitive z score at age 60, but had  
314 0.10 (0.02 to 0.18) standard deviations lower global cognitive z score at age 80, and 0.19  
315 (0.03 to 0.35) standard deviations lower score at age 90 (Table 3). Results were similar after  
316 further adjusting for behavioural and biomedical risk factors at baseline (Figure S2, Table S1).

317

### 318 **Backward trajectory of cardiac troponin I before dementia**

319 Among the 695 incident dementia cases identified in the study sample, all were successfully  
320 matched to 4 controls and this led to a nested case-control sample of 3475 individuals. Both  
321 case and control groups had an increasing predicted cardiac troponin I level over time, which  
322 were not significantly different, though they tended to converge (interaction  $P=0.12$ ) (Figure  
323 2). Compared with controls, cases had consistently higher mean cardiac troponin I levels  
324 from 25 years to 7 years preceding dementia diagnosis (Table S2). Further matching by  
325 cardiovascular disease status showed similar but attenuated results (Figure S3, Table S3).

326

### 327 **Association between cardiac troponin I at baseline and brain volume**

328 Of the 771 participants in the substudy, we excluded those without a cardiac troponin I  
329 measurement ( $n=129$ ), or who had dementia or cardiovascular disease at baseline ( $n=1$ ),  
330 producing an analytical sample of 641. One year older age was associated with 0.32%  
331 (95%CI: 0.28 to 0.35%) lower total brain volume, 0.23% (95%CI: 0.20 to 0.26%) lower grey  
332 matter volume, and 0.09% (95%CI: 0.06 to 0.11%) lower white matter volume. Higher  
333 cardiac troponin I level at baseline was associated with lower grey matter volume, but not  
334 with white matter volume. People with cardiac troponin I concentrations  $>5.2$  ng/L had 0.63%  
335 (95%CI: 0.23 to 1.04%) lower grey matter volume and 18% (95%CI: 0 to 40%) increased  
336 risk of hippocampal atrophy compared with those with cardiac troponin I  $<2.5$  ng/L,  
337 corresponding to an age effect of 2.7 and 3 years, respectively (Table 4). Cardiac troponin I  
338 concentration was not associated with white matter hyperintensities.

339

### 340 **Discussion**

341 Our longitudinal study suggests that subclinical myocardial injury in midlife, indicated by  
342 elevated cardiac troponin I levels, is associated with higher dementia risk. We have three key  
343 findings. First, people with higher cardiac troponin I concentrations at baseline had faster  
344 decline of cognition and were more likely to be diagnosed with dementia over a median 25  
345 years of follow-up. Second, backward trajectory analysis showed that cardiac troponin I level  
346 was consistently higher in those who developed dementia compared to those who did not  
347 between 7 and 25 years before diagnosis. The length of time suggests that higher cardiac  
348 troponin I is unlikely to be due to prodromal changes, and it may be on the causal pathway.  
349 Third, in the MRI substudy, people with increased cardiac troponin I at the midlife baseline  
350 were more likely to have relatively low grey matter volume and hippocampal atrophy 15  
351 years later. These three consistent findings involving repeated assessments with a high-

352 sensitivity cardiac troponin I assay starting in midlife strengthen the evidence that myocardial  
353 injury may directly or indirectly contribute to the aetiology of dementia.

#### 354 **Comparison with previous studies**

355 Two published studies have examined the prospective association of cardiac troponin with  
356 incident dementia.<sup>20</sup> The Atherosclerosis Risk in Communities (ARIC) study found that  
357 elevated levels of high-sensitivity cardiac troponin T measured at mean age of 62.5 years  
358 were associated with higher dementia incidence over 13 years of follow-up.<sup>10</sup> The national  
359 FINRISK 1997 study reported that high-sensitivity cardiac troponin I measured at a mean age  
360 of 47.9 years was associated with incident dementia over 18 years of follow-up.<sup>21</sup> Our study  
361 had longer follow-up and larger effect size compared with FINRISK using high-sensitivity  
362 troponin I (Abbott Architect), but a smaller effect size compared with the ARIC study using  
363 high-sensitivity troponin T (Roche Elecsys). These previous studies were based on a single  
364 measurement of cardiac troponin.

365 Our novel contribution to the evidence is based on repeated measurements of cardiac  
366 troponin I over a 15-year period which allowed the backward trajectory before dementia  
367 diagnosis to be modelled. We observed an increased cardiac troponin level occurred as early  
368 as 25 years before dementia diagnosis. Further, our characterisation of cognitive decline,  
369 based on six assessments of cognitive function over 25 years substantiates the interpretation  
370 that subclinical myocardial injury is associated with long-run processes in the midlife  
371 preclinical period.

372 A few prospective studies found higher cardiac troponin T concentration at baseline was  
373 associated with faster annual decline in global cognition. However, these studies either had  
374 cardiac troponin measured at older age (>65 years)<sup>11,12,22</sup> or had few repeated measurements  
375 of cognitive function (<3 times),<sup>23</sup> or had a short follow-up time (<5 years).<sup>11,12</sup> Consequently,  
376 no previous study investigated the effect of the cardiac troponin at midlife on the subsequent  
377 long-term cognitive trajectory until late life. Our study measured cardiac troponin I at a mean  
378 age of 56 years and had up to 6 repeated measurements of cognitive function across 25 years  
379 and found that cognitive performance was not significantly different in the 60s and 70s, but  
380 started to diverge around age 80. This is consistent with the finding from the ARIC study that  
381 cardiac troponin T measured at a mean age of 63 years was not associated with 15-year  
382 change in cognitive function using only two repeated cognitive function measured 15 years  
383 apart.<sup>23</sup>

384 Few population-based studies have examined the association between cardiac troponin and  
385 structural brain changes, and cardiac troponin T assays were mostly used that have greater  
386 imprecision than high-sensitivity cardiac troponin I assays at the low concentrations observed  
387 in population studies.<sup>24</sup> A cross-sectional study using data from the Maastricht study found  
388 that a higher cardiac troponin T concentration was associated with smaller grey matter  
389 volume and greater white matter hyperintensity among participants aged 60 and above.<sup>25</sup> The  
390 ARIC study reported that individuals with higher cardiac troponin T was associated with  
391 MRI-defined silent brain infarcts and white matter lesions cross-sectionally and more white  
392 matter lesions progression on the follow-up MRI 11 years later.<sup>26</sup> Our study used a high-  
393 sensitivity cardiac troponin I assay with consistent findings in regards to the smaller grey  
394 matter in those with higher cardiac troponin levels. A potential explanation is that grey matter  
395 is more susceptible to cerebral hypoperfusion caused by cardiac dysfunction as it has higher  
396 metabolic demand compared with white matter. Our study, however, did not find cardiac  
397 troponin to be associated with white matter hyperintensity. This is consistent with the  
398 previous evidence from the Whitehall II study that the life Simple 7 cardiovascular health  
399 score was not associated with white matter hyperintensities.<sup>5</sup> A recent study using UK  
400 Biobank, however, found that higher Life Essential 8 cardiovascular health score was  
401 associated with lower white matter hyperintensity volume.<sup>27</sup> This reflects that cardiac  
402 troponin may capture different aspects of cardiac dysfunction compared to cardiovascular  
403 health scores. Different methods used to measure white matter hyperintensity may also  
404 explain these inconsistent observations.

#### 405 **Role of subclinical myocardial injury in dementia aetiology**

406 Dementia and cardiovascular disease share risk factors such as hypertension and  
407 hyperlipidemia.<sup>3,28-30</sup> These risk factors may contribute to the heart-brain connection by  
408 causing damage to vessels in both organs. Importantly, our analysis shows that higher cardiac  
409 troponin was associated with higher dementia risk independent of hypertension and  
410 hyperlipidaemia. Higher cardiac troponin is associated with increased risk of stroke,<sup>31</sup> and  
411 stroke is known to double the risk of dementia.<sup>32</sup> Interestingly, the effect was only slightly  
412 attenuated when adjusting for clinically diagnosed cardiovascular disease in our study,  
413 indicating other mechanisms beyond occlusion of major arteries, such as cerebral small  
414 vessel disease and cerebral hypoperfusion and hypoxia, may be involved.<sup>3,33</sup> A previous  
415 review concluded that cardiac troponins are more consistently linked to vascular brain lesions  
416 than to neurodegenerative changes such as brain atrophy.<sup>2</sup> However, we found that cardiac

417 troponin was prospectively associated with brain atrophy. It is possible that vascular and  
418 neurodegenerative brain damage may overlap and develop in parallel<sup>34</sup> and cardiac troponin  
419 may provide insights into both pathologic processes.

## 420 **Strengths and limitations**

421 Our study, with a median follow-up of 25 years, is less susceptible to reverse causation. The  
422 development of dementia involves a long prodromal period, and neuropathological  
423 abnormality and change of biomarker levels can begin 15 to 20 years before clinical  
424 diagnosis of dementia. No other population-based studies have measured cardiac troponin  
425 level at midlife with a follow-up period of 20 years, which is critical to examine the  
426 association between subclinical myocardial injury in midlife and incident dementia.

427 Another novel strength is the incorporation of repeated measurements of high-sensitivity  
428 cardiac troponin I and modelling the backward trajectory of cardiac troponin before dementia  
429 diagnosis. Previous studies only focused cardiac troponin level at one time point, and its  
430 association with incident dementia depends on both when cardiac troponin was measured and  
431 the length of the follow-up period. This conventional study design cannot determine the  
432 length of time that cardiac troponin levels have been raised before dementia diagnosis.

433 Our results may underestimate the association as cardiac troponin is associated with mortality,  
434 although we would have picked up some of these people if dementia was recorded on the  
435 death certificate. Troponin I levels can be elevated due to other causes that cardiac muscle  
436 pathology such as intense exercise, but this would not be expected to increase the risk of  
437 dementia. The population in Whitehall II are predominantly white, and generalisation of our  
438 results to other ethnicity groups should be cautious. We used one cardiac troponin I assay,  
439 and validation of our results using other cardiac troponin assays is needed if measurement  
440 were to be used in clinical practice to inform dementia risk.

## 441 **Conclusion**

442 Subclinical myocardial injury at midlife is associated with higher dementia incidence in later  
443 life. Measurement of cardiac troponin I using a high-sensitivity assay in midlife may be  
444 useful in the early identification of a population at risk of cognitive decline and dementia.

445

## 446 **Acknowledgements**

447 We thank all of the participating civil service departments and their welfare, personnel, and  
448 establishment officers; the British Occupational Health and Safety Agency; the British  
449 Council of Civil Service Unions; all participating civil servants in the Whitehall II study; and  
450 all members of the Whitehall II Study team at UCL and Oxford.

#### 451 **Contributors**

452 YC and EJB conceptualised and designed the study. YC and MS did the statistical analysis.  
453 YC wrote the first draft of the manuscript. All authors interpreted the data and critically  
454 revised the manuscript. All authors approved the final version of the manuscript for  
455 submission. YC and EJB are the guarantors. The corresponding author attests that all listed  
456 authors meet authorship criteria and that no others meeting the criteria have been omitted.

#### 457 **Funding**

458 The Whitehall II study has been supported by grants from the Wellcome Trust, UK  
459 (221854/Z/20/Z), the UK Medical Research Council (Y014154, K013351, R024227,  
460 S011676); the British Heart Foundation (PG/11/63/29011, RG/13/2/30098, RG/16/11/32334);  
461 the British Health and Safety Executive; the British Department of Health; the National Heart,  
462 Lung, and Blood Institute (R01HL036310); the National Institute on Aging, National  
463 Institute of Health (R01AG013196, R01AG034454); the Economic and Social Research  
464 Council (ES/J023299). The Whitehall II imaging substudy (KPE) was supported by the  
465 Medical Research Council (G1001354), the HDH Wills 1965 Charitable Trust (English  
466 Charity No 1117747), and the Gordon Edward Small's Charitable Trust (Scottish Charity No  
467 SC008962). DMK is supported by the British Heart Foundation through an Intermediate  
468 Basic Science Research Fellowship. NLM is supported by the British Heart Foundation  
469 through a Chair Award (CH/F/21/90010), Programme Grant (RG/20/10/34966), and a  
470 Research Excellence Award (RE/24/130012). The study was supported by an investigator-  
471 initiated study grant from the Siemens Healthineers to the University of Edinburgh. YC is  
472 supported by the Wellcome Early-Career Award (227639/Z/23/Z). EJB was supported by the  
473 Economic and Social Research Council (ES/T014377).

#### 474 **Ethical approval**

475 Written informed consent from participants and research ethics approvals were renewed at  
476 each contact. Ethical approval was from the University College London Hospital Committee  
477 on the Ethics of Human Research (reference number 85/0938).

478 **Competing interests**

479 All authors have completed the ICMJE uniform disclosure form at  
480 [www.icmje.org/disclosure-of-interest/](http://www.icmje.org/disclosure-of-interest/) and declare: support for the Whitehall II study from  
481 the Wellcome Trust, the National Institute on Aging, NIH, the British Heart Foundation and  
482 UK Medical Research Council; no financial relationships with any organisations that might  
483 have an interest in the submitted work in the previous three years; no other relationships or  
484 activities that could appear to have influenced the submitted work. KPE reports receiving  
485 consulting fees for being in the expert panel for European Research Council, Flemish Science  
486 Foundation, and European Science Foundation. JD reports consulting fees and honoraria  
487 from Amgen, AstraZeneca, Boehringer Ingelheim, Merck, Pfizer, Aegerion, Novartis, Sanofi,  
488 Takeda, Novo Nordisk, and Bayer. NLM reports honoraria from Abbott Diagnostics, Siemens  
489 Healthineers, and Roche Diagnostics.

490 **Transparency declaration**

491 The manuscript is an honest, accurate, and transparent account of the study being reported.  
492 No important aspects of the study have been omitted. Any discrepancies from the study as  
493 originally planned (and, if relevant, registered) have been explained.

494



## 495 **References**

- 496 1 Zhao B, Li T, Fan Z, *et al.* Heart-brain connections: Phenotypic and genetic insights from  
497 magnetic resonance images. *Science* 2023; **380**: abn6598.
- 498 2 Jensen M, Zeller T, Twerenbold R, Thomalla G. Circulating cardiac biomarkers, structural  
499 brain changes, and dementia: Emerging insights and perspectives. *Alzheimers Dement* 2023;  
500 **19**: 1529–48.
- 501 3 Qiu C, Fratiglioni L. A major role for cardiovascular burden in age-related cognitive decline.  
502 *Nat Rev Cardiol* 2015; **12**: 267–77.
- 503 4 Livingston G, Huntley J, Liu KY, *et al.* Dementia prevention, intervention, and care: 2024  
504 report of the Lancet standing Commission. *The Lancet* 2024; **404**: 572–628.
- 505 5 Sabia S, Fayosse A, Dumurgier J, *et al.* Association of ideal cardiovascular health at age 50  
506 with incidence of dementia: 25 year follow-up of Whitehall II cohort study. *BMJ* 2019; **366**:  
507 14414.
- 508 6 Jefferson AL, Beiser AS, Himali JJ, *et al.* Low Cardiac Index Is Associated With Incident  
509 Dementia and Alzheimer Disease. *Circulation* 2015; **131**: 1333–9.
- 510 7 Neumann JT, Twerenbold R, Weimann J, *et al.* Prognostic Value of Cardiovascular  
511 Biomarkers in the Population. *JAMA* 2024; **331**: 1898–909.
- 512 8 Blankenberg S, Salomaa V, Makarova N, *et al.* Troponin I and cardiovascular risk  
513 prediction in the general population: the BiomarCaRE consortium. *Eur Heart J* 2016; **37**:  
514 2428–37.
- 515 9 de Bakker M, Anand A, Shipley M, *et al.* Sex Differences in Cardiac Troponin Trajectories  
516 Over the Life Course. *Circulation* 2023; **147**: 1798–808.
- 517 10 Schneider ALC, Rawlings AM, Sharrett AR, *et al.* High-sensitivity cardiac troponin T and  
518 cognitive function and dementia risk: the atherosclerosis risk in communities study. *Eur*  
519 *Heart J* 2014; **35**: 1817–24.
- 520 11 Bertens AS, Sabayan B, de Craen AJM, Van der Mast RC, Gussekloo J. High Sensitivity  
521 Cardiac Troponin T and Cognitive Function in the Oldest Old: The Leiden 85-Plus Study. *J*  
522 *Alzheimers Dis* 2017; **60**: 235–42.
- 523 12 Wijsman LW, de Craen AJ, Trompet S, *et al.* High-sensitivity cardiac troponin T is  
524 associated with cognitive decline in older adults at high cardiovascular risk. *Eur J Prev*  
525 *Cardiol* 2016; **23**: 1383–92.
- 526 13 Kimenai DM, Anand A, de Bakker M, *et al.* Trajectories of cardiac troponin in the  
527 decades before cardiovascular death: a longitudinal cohort study. *BMC Medicine* 2023; **21**:  
528 216.
- 529 14 Wilson RS, Leurgans SE, Boyle PA, Schneider JA, Bennett DA. Neurodegenerative basis  
530 of age-related cognitive decline (e-Pub ahead of print)(CME). *Neurology* 2010; **75**: 1070–8.

- 531 15 Filippini N, Zsoldos E, Haapakoski R, *et al.* Study protocol: the Whitehall II imaging sub-  
532 study. *BMC Psychiatry* 2014; **14**: 159.
- 533 16 Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at  
534 1.5 T in Alzheimer's dementia and normal aging. *AJR Am J Roentgenol* 1987; **149**: 351–6.
- 535 17 Scheltens P, Leys D, Barkhof F, *et al.* Atrophy of medial temporal lobes on MRI in  
536 'probable' Alzheimer's disease and normal ageing: diagnostic value and  
537 neuropsychological correlates. *J Neurol Neurosurg Psychiatry* 1992; **55**: 967–72.
- 538 18 Bloomberg M, Dugravot A, Dumurgier J, *et al.* Sex differences and the role of education  
539 in cognitive ageing: analysis of two UK-based prospective cohort studies. *Lancet Public*  
540 *Health* 2021; **6**: e106–15.
- 541 19 Proust-Lima C, Philipps V, Liqueur B. Estimation of Extended Mixed Models Using Latent  
542 Classes and Latent Processes: The R Package lcmm. *Journal of Statistical Software* 2017;  
543 **78**: 1–56.
- 544 20 Zonneveld MH, Abbel D, le Cessie S, Jukema JW, Noordam R, Trompet S. Cardiac  
545 Troponin, Cognitive Function, and Dementia: A Systematic Review. *Aging Dis* 2023; **14**:  
546 386–97.
- 547 21 Tynkkynen J, Hernesniemi JA, Laatikainen T, *et al.* High-sensitivity cardiac troponin I  
548 and NT-proBNP as predictors of incident dementia and Alzheimer's disease: the FINRISK  
549 Study. *J Neurol* 2017; **264**: 503–11.
- 550 22 von Rennenberg R, Liman T, Nolte CH, *et al.* High-Sensitivity Cardiac Troponin T and  
551 Cognitive Decline in Older Adults: Results of the Berlin Aging Study II. *Gerontology* 2023;  
552 **69**: 140–8.
- 553 23 Pokharel Y, Mouhanna F, Schneider ALC, *et al.* High-Sensitive Troponin T, Natriuretic  
554 Peptide, and Cognitive Change. *J Am Geriatr Soc* 2019; **67**: 2353–61.
- 555 24 Apple FS, Collinson PO, for the IFCC Task Force on Clinical Applications of Cardiac  
556 Biomarkers. Analytical Characteristics of High-Sensitivity Cardiac Troponin Assays.  
557 *Clinical Chemistry* 2012; **58**: 54–61.
- 558 25 Veugen MGJ, Henry RMA, Brunner-La Rocca H-P, *et al.* Cross-Sectional Associations  
559 Between Cardiac Biomarkers, Cognitive Performance, and Structural Brain Changes Are  
560 Modified by Age. *Arterioscler Thromb Vasc Biol* 2018; **38**: 1948–58.
- 561 26 Dadu RT, Fornage M, Virani SS, *et al.* Cardiovascular Biomarkers and Subclinical Brain  
562 Disease in the Atherosclerosis Risk in Communities (ARIC) Study. *Stroke* 2013; **44**: 1803–  
563 8.
- 564 27 Zhou R, Chen H-W, Li F-R, Zhong Q, Huang Y-N, Wu X-B. 'Life's Essential 8'  
565 Cardiovascular Health and Dementia Risk, Cognition, and Neuroimaging Markers of Brain  
566 Health. *J Am Med Dir Assoc* 2023; **24**: 1791–7.
- 567 28 Janssen E, de Leeuw F-E. Getting to the Heart of the Heart-Brain Connection. *Neurology*  
568 2023; **101**: 57–8.

- 569 29 Chen Y, Araghi M, Bandosz P, *et al.* Impact of Hypertension Prevalence Trend on  
570 Mortality and Burdens of Dementia and Disability in England and Wales to 2060:  
571 Modelling Study. 2023; published online Feb 17. DOI:10.2139/ssrn.4356790.
- 572 30 Abell JG, Kivimäki M, Dugravot A, *et al.* Association between systolic blood pressure  
573 and dementia in the Whitehall II cohort study: role of age, duration, and threshold used to  
574 define hypertension. *Eur Heart J* 2018; **39**: 3119–25.
- 575 31 Broersen LHA, Stengl H, Nolte CH, *et al.* Association Between High-Sensitivity Cardiac  
576 Troponin and Risk of Stroke in 96 702 Individuals: A Meta-Analysis. *Stroke* 2020; **51**:  
577 1085–93.
- 578 32 Kuźma E, Lourida I, Moore SF, Levine DA, Ukoumunne OC, Llewellyn DJ. Stroke and  
579 dementia risk: A systematic review and meta-analysis. *Alzheimers Dement* 2018; **14**: 1416–  
580 26.
- 581 33 Zhao D, Guallar E, Qiao Y, *et al.* Intracranial Atherosclerotic Disease and Incident  
582 Dementia: The ARIC Study (Atherosclerosis Risk in Communities). *Circulation* 2024; **150**:  
583 838–47.
- 584 34 Song R, Pan K-Y, Xu H, *et al.* Association of cardiovascular risk burden with risk of  
585 dementia and brain pathologies: a population-based cohort study. *Alzheimers Dement* 2021;  
586 **17**: 1914–22.
- 587

588 **Figure legends**

589 Figure 1 Cognitive trajectories from age 50 to 89 years by levels of high-sensitivity cardiac troponin I  
590 at baseline stratified by birth cohort. Predicted cognitive scores estimated from a mixed model (model  
591 terms: sex, ethnicity, education level, occupational position, birth cohort, age, age<sup>2</sup>, and interactions of  
592 all covariates with age and age<sup>2</sup>). P for difference in trajectory between different cardiac troponin  
593 levels: 0.0012

594

595 Figure 2 Averaged predicted trajectories of high-sensitivity cardiac troponin I (ng/L, log2 transformed)  
596 for 695 incident cases of dementia and 2780 matched controls over 25 years preceding diagnosis of  
597 dementia estimated from a latent process mixed model. Nested case-control design matching with age,  
598 sex and education level. Dashed lines represent 95% CIs. P for difference in trajectory between cases  
599 and controls: 0.12

600

601 Table 1 Characteristics of the study sample

	High-sensitivity cardiac troponin I at baseline		Dementia status at the end of follow-up		Total population (n=5985)
	≤3.4 ng/L (n=3417)	>3.4 ng/L (n=2568)	No dementia (n=5379)	Dementia (n=606)	
<b>Age, years</b>	55.3 (5.8)	57.5 (6.1)	55.7 (5.9)	61.1 (5.1)	56.2 (6.0)
<b>Women</b>	1351 (39.5)	398 (15.5)	1539 (28.6)	210 (34.7)	1749 (29.2)
<b>Ethnicity, White</b>	3142 (92.0)	2350 (91.5)	4960 (92.2)	532 (87.8)	5492 (91.8)
<b>Education</b>					
Less than secondary school	1277 (37.4)	852 (33.2)	1847 (34.3)	282 (46.5)	2129 (35.6)
Secondary school	890 (26.0)	701 (27.3)	1455 (27.0)	136 (22.4)	1591 (26.6)
University	1189 (34.8)	958 (37.3)	1971 (36.6)	176 (29.0)	2147 (35.9)
<b>Occupation position</b>					
Low	520 (15.2)	260 (10.1)	646 (12.0)	134 (22.1)	780 (13.0)
Intermediate	1506 (44.1)	1036 (40.3)	2308 (42.9)	234 (38.6)	2542 (42.5)
High	1347 (39.4)	1245 (48.5)	2361 (43.9)	231 (38.1)	2592 (43.3)
<b>Alcohol consumption</b>					
Non-drinkers	556 (16.3)	331 (12.9)	757 (14.1)	130 (21.5)	887 (14.8)
Moderate	1960 (57.4)	1539 (59.9)	3175 (59.0)	324 (53.5)	3499 (58.5)
heavy	788 (23.1)	617 (24.0)	1271 (23.6)	134 (22.1)	1405 (23.5)
<b>Smoking status</b>					
Never	1679 (49.1)	1264 (49.2)	2644 (49.2)	299 (49.3)	2943 (49.2)
Former	1300 (38.0)	1079 (42.0)	2128 (39.6)	251 (41.4)	2379 (39.7)
Current	382 (11.2)	183 (7.1)	515 (9.6)	50 (8.3)	565 (9.4)
<b>Physical activity, Hours per week</b>					
Low	1129 (33.0)	634 (24.7)	1564 (29.1)	199 (32.8)	1763 (29.5)
Moderate	588 (17.2)	379 (14.8)	878 (16.3)	89 (14.7)	967 (16.2)
high	1615 (47.3)	1484 (57.8)	2791 (51.9)	308 (50.8)	3099 (51.8)
<b>Diabetes</b>	94 (2.8)	63 (2.5)	129 (2.4)	28 (4.6)	157 (2.6)
<b>BMI, kg/m<sup>2</sup></b>	25.9 (4.0)	26.4 (3.8)	26.1 (3.9)	26.3 (4.1)	26.1 (3.9)
<b>SBP, mmHg</b>	121 (15.3)	127 (17.5)	123 (16.5)	126 (16.6)	123 (16.5)
<b>DBP, mmHg</b>	76.4 (9.9)	79.0 (11.2)	77.6 (10.5)	77.4 (10.4)	77.5 (10.5)
<b>Glucose, mmol/L</b>	5.2 (1.2)	5.3 (1.2)	5.2 (1.2)	5.4 (1.6)	5.2 (1.2)
<b>Total cholesterol, mmol/L</b>	5.9 (1.0)	5.9 (1.1)	5.9 (1.0)	6.1 (1.1)	5.9 (1.1)

602 Values are means (SDs) for continuous variables and numbers (percentages) for categorical variables

603

604 Table 2 Association between high-sensitivity cardiac troponin I at baseline (1997-99) and incident  
605 dementia during 25 years of follow-up

<b>Cardiac troponin I, ng/L</b>	<b>No of cases/total No</b>	<b>HR (95% CI)</b>
<2.5	158/2135	1.00 (reference)
2.5-3.4	133/1282	1.22 (0.96,1.54)
3.5-5.2	150/1281	<b>1.34 (1.06,1.70)</b>
>5.2	165/1287	<b>1.43 (1.13,1.80)</b>

606 The model was adjusted for age, sex, ethnicity, education, occupational position, smoking status,  
607 alcohol consumption, physical activity, BMI, systolic blood pressure, diastolic blood pressure,  
608 glucose, and total cholesterol.

609 Table 3 Association of high-sensitivity cardiac troponin I with cognitive performance at age 60, 70,  
610 80, and 90 years.

<b>Difference in cognitive function</b>				
	<b>Age 60</b>	<b>Age 70</b>	<b>Age 80</b>	<b>Age 90</b>
<b>Cardiac troponin I, ng/L</b>				
<2.5	ref	ref	ref	ref
2.5-3.4	0 (-0.05,0.05)	-0.04 (-0.09,0.02)	-0.03 (-0.11,0.04)	0 (-0.15,0.16)
3.5-5.2	-0.02 (-0.08,0.03)	<b>-0.06 (-0.11,0)</b>	-0.06 (-0.14,0.01)	-0.05 (-0.21,0.10)
>5.2	0 (-0.06,0.05)	-0.04 (-0.09,0.02)	<b>-0.10 (-0.18,-0.02)</b>	<b>-0.19 (-0.35,-0.03)</b>

611

612

Table 4 Association between high-sensitivity cardiac troponin I at phase 5 (1997-99) and structural brain volume 15 years later: Whitehall II imaging substudy (n=641)

Cardiac troponin I, ng/L	No	Total brain volume (Grey matter + White matter) (% total intracranial volume)	Grey matter volume (% total intracranial volume)	Hippocampal atrophy (Scheltens score summed across both sides, range 0-8)
		Difference (95%CI)	Difference (95%CI)	Ratio of the score (95%CI)
<2.5	220	0 (ref)	0 (ref)	1 (ref)
2.5-3.4	144	-0.34 (-0.83,0.14)	<b>-0.44 (-0.83,-0.04)</b>	1.03 (0.87,1.23)
3.5-5.2	136	-0.38 (-0.88,0.11)	<b>-0.62 (-1.03,-0.22)</b>	1.16 (0.98,1.38)
>5.2	141	<b>-0.65 (-1.14,-0.15)</b>	<b>-0.63 (-1.04,-0.23)</b>	<b>1.18 (1,1.40)</b>
Every doubling in cardiac troponin I	641	-0.10 (-0.26,0.06)	<b>-0.13 (-0.26,0.00)</b>	1.03 (0.98,1.09)

For total brain volume, grey matter volume and white matter volume, linear regression models were used adjusted for age, sex, ethnicity, education level, occupational position, smoking status, alcohol consumption, and magnetic resonance imaging scanner.

For total white matter hyperintensities and hippocampal atrophy, Poisson regressions were used adjusted for age, sex, ethnicity, education level, occupational position, smoking status, alcohol consumption, and magnetic resonance imaging scanner.

We did not find significant results for white matter volume and total white matter hyperintensities.





